+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Psoriasis Drugs Market Size, Share & Trends Analysis Report by Class, Treatment (Topicals, Systemic, Biologics), Route of Administration (Oral, Parenteral), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 150 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 6098120
Description Jump to:
The Psoriasis Drugs Market was valued at USD 21.12 billion in 2024, and is projected to reach USD 39.11 billion by 2030, rising at a CAGR of 10.94%. Rising disease awareness, an increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, the expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping the hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of the site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

The incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. The rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

Psoriasis Drugs Market Report Highlights

  • Tumor necrosis factor inhibitors dominated the market and accounted for a share of 40.88% in 2024 as they effectively target the inflammatory pathways crucial to the disease, resulting in major enhancements.
  • The biologics segment dominated the market in 2024 with a share of 46.38% as they are highly selective to certain immune pathways in connection to psoriasis and massive improvements in disease management compared to traditional medicines.
  • The topical segment is expected to register a significant growth rate over the forecast period.
  • The parenteral segment dominated the market, accounting for a 41.58% share in 2024.
  • The hospital pharmacies segment accounted for a leading share of the psoriasis drugs industry in 2024.
  • North America psoriasis drugs market held a leading market position in 2024, accounting for 38.65% of the global share.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Class
1.2.2. Treatment
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Psoriasis Drug Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Psoriasis Drug Market: Class Business Analysis
4.1. Class Market Share, 2025 & 2030
4.2. Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Class, 2018 to 2030 (USD Million)
4.4. Tumor Necrosos Factor Inhibitors
4.4.1. Tumor Necrosos Factor Inhibitors Market, 2018-2030 (USD Million)
4.5. Interleukin Inhibitors
4.5.1. Interleukin Inhibitors Market, 2018-2030 (USD Million)
4.6. Vitamin D Analogues
4.6.1. Vitamin D Analogues Market, 2018-2030 (USD Million)
4.7. Corticosteroids
4.7.1. Corticosteroids Market, 2018-2030 (USD Million)
4.8. Others
4.8.1. Other Class Market, 2018-2030 (USD Million)
Chapter 5. Psoriasis Drug Market: Treatment Business Analysis
5.1. Treatment Market Share, 2025 & 2030
5.2. Treatment Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
5.4. Topicals
5.4.1. Topicals Market, 2018-2030 (USD Million)
5.5. Systemic
5.5.1. Systemic Market, 2018-2030 (USD Million)
5.6. Biologics
5.6.1. Biologics Market, 2018-2030 (USD Million)
Chapter 6. Psoriasis Drug Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2025 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Oral
6.4.1. Oral Market, 2018-2030 (USD Million)
6.5. Parental
6.5.1. Parental Market, 2018-2030 (USD Million)
6.6. Topical
6.6.1. Tropical Market, 2018-2030 (USD Million)
Chapter 7. Psoriasis Drug Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2025 & 2030
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2018-2030 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail Pharmacies Market, 2018-2030 (USD Million)
7.6. Other Pharmacies
7.6.1. Others Pharmacies Market, 2018-2030 (USD Million)
Chapter 8. Psoriasis Drug Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2025 & 2030
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
8.4. North America
8.4.1. North America Psoriasis Drug Market Estimates And Forecasts, By Country, 2018-2030 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Regulatory Framework
8.4.2.4. Reimbursement Framework
8.4.2.5. U.S. Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Regulatory Framework
8.4.3.4. Reimbursement Framework
8.4.3.5. U.S. Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Regulatory Framework
8.4.4.4. Reimbursement Framework
8.4.4.5. Mexico Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5. Europe
8.5.1. Europe Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement Framework
8.5.2.5. Uk Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement Framework
8.5.3.5. Germany Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Regulatory Framework
8.5.4.4. Reimbursement Framework
8.5.4.5. France Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Regulatory Framework
8.5.5.4. Reimbursement Framework
8.5.5.5. Italy Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Target Disease Prevalence
8.5.6.3. Regulatory Framework
8.5.6.4. Reimbursement Framework
8.5.6.5. Spain Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.7. Denmark
8.5.7.1. Key Country Dynamics
8.5.7.2. Target Disease Prevalence
8.5.7.3. Regulatory Framework
8.5.7.4. Reimbursement Framework
8.5.7.5. Denmark Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.8. Sweden
8.5.8.1. Key Country Dynamics
8.5.8.2. Target Disease Prevalence
8.5.8.3. Regulatory Framework
8.5.8.4. Reimbursement Framework
8.5.8.5. Sweden Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. Target Disease Prevalence
8.5.9.3. Regulatory Framework
8.5.9.4. Reimbursement Framework
8.5.9.5. Norway Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement Framework
8.6.2.5. Japan Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement Framework
8.6.3.5. China Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement Framework
8.6.4.5. India Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement Framework
8.6.5.5. Australia Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.6. South Korea
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Regulatory Framework
8.6.6.4. Reimbursement Framework
8.6.6.5. South Korea Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Target Disease Prevalence
8.6.7.3. Regulatory Framework
8.6.7.4. Reimbursement Framework
8.6.7.5. Thailand Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7. Latin America
8.7.1. Latin America Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Target Disease Prevalence
8.7.2.3. Regulatory Framework
8.7.2.4. Reimbursement Framework
8.7.2.5. Japan Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Target Disease Prevalence
8.7.3.3. Regulatory Framework
8.7.3.4. Reimbursement Framework
8.7.3.5. China Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8. Middle East and Africa
8.8.1. Middle East and Africa Psoriasis Drug Market Estimates and Forecasts, 2017-2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Target Disease Prevalence
8.8.2.3. Regulatory Framework
8.8.2.4. Reimbursement Framework
8.8.2.5. South Africa Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Target Disease Prevalence
8.8.3.3. Regulatory Framework
8.8.3.4. Reimbursement Framework
8.8.3.5. Saudi Arabia Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Target Disease Prevalence
8.8.4.3. Regulatory Framework
8.8.4.4. Reimbursement Framework
8.8.4.5. UAE Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Target Disease Prevalence
8.8.5.3. Regulatory Framework
8.8.5.4. Reimbursement Framework
8.8.5.5. Kuwait Psoriasis Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. AbbVie Inc.
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Amgen Inc.
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Johnson & Johnson Services, Inc.
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Novartis AG
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Eli Lilly and Company
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. AstraZeneca
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Celgene Corporation
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. UCB S.A.
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Merck
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Boehringer Ingelheim International GmbH
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Psoriasis market, by region, 2018-2030 (USD Million)
Table 4 Global Psoriasis market, by class, 2018-2030 (USD Million)
Table 5 Global Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 6 Global Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 7 Global Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 8 North America Psoriasis market, by country, 2018-2030 (USD Million)
Table 9 North America Psoriasis market, by class, 2018-2030 (USD Million)
Table 10 North America Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 11 North America Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 12 North America Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 13 U.S. Psoriasis market, by class, 2018-2030 (USD Million)
Table 14 U.S. Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 15 U.S. Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 16 U.S. Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 17 Canada Psoriasis market, by class, 2018-2030 (USD Million)
Table 18 Canada Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 19 Canada Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 20 Canada Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 21 Mexico Psoriasis market, by class, 2018-2030 (USD Million)
Table 22 Mexico Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 23 Mexico Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 24 Mexico Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 25 Europe Psoriasis market, by country, 2018-2030 (USD Million)
Table 26 Europe Psoriasis market, by class, 2018-2030 (USD Million)
Table 27 Europe Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 28 Europe Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 29 Europe Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 30 UK Psoriasis market, by class, 2018-2030 (USD Million)
Table 31 UK Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 32 UK Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 33 UK Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 34 Germany Psoriasis market, by class, 2018-2030 (USD Million)
Table 35 Germany Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 36 Germany Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 37 Germany Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 38 France Psoriasis market, by class, 2018-2030 (USD Million)
Table 39 France Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 40 France Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 41 France Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 42 Italy Psoriasis market, by class, 2018-2030 (USD Million)
Table 43 Italy Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 44 Italy Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 45 Italy Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 46 Spain Psoriasis market, by class, 2018-2030 (USD Million)
Table 47 Spain Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 48 Spain Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 49 Spain Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 50 Norway Psoriasis market, by class, 2018-2030 (USD Million)
Table 51 Norway Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 52 Norway Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 53 Norway Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 54 Denmark Psoriasis market, by class, 2018-2030 (USD Million)
Table 55 Denmark Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 56 Denmark Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 57 Denmark Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 58 Sweden Psoriasis market, by class, 2018-2030 (USD Million)
Table 59 Sweden Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 60 Sweden Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 61 Sweden Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 62 Asia Pacific Psoriasis market, by country, 2018-2030 (USD Million)
Table 63 Asia Pacific Psoriasis market, by class, 2018-2030 (USD Million)
Table 64 Asia Pacific Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 65 Asia Pacific Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 66 Asia Pacific Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 67 Japan Psoriasis market, by class, 2018-2030 (USD Million)
Table 68 Japan Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 69 Japan Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 70 Japan Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 71 China Psoriasis market, by class, 2018-2030 (USD Million)
Table 72 China Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 73 China Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 74 China Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 75 India Psoriasis market, by class, 2018-2030 (USD Million)
Table 76 India Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 77 India Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 78 India Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 79 Australia Psoriasis market, by class, 2018-2030 (USD Million)
Table 80 Australia Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 81 Australia Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 82 Australia Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 83 South Korea Psoriasis market, by class, 2018-2030 (USD Million)
Table 84 South Korea Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 85 South Korea Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 86 South Korea Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 87 Thailand Psoriasis market, by class, 2018-2030 (USD Million)
Table 88 Thailand Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 89 Thailand Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 90 Thailand Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 91 Latin America Psoriasis market, by country, 2018-2030 (USD Million)
Table 92 Latin America Psoriasis market, by class, 2018-2030 (USD Million)
Table 93 Latin America Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 94 Latin America Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 95 Latin America Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 96 Brazil Psoriasis market, by class, 2018-2030 (USD Million)
Table 97 Brazil Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 98 Brazil Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 99 Brazil Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 100 Argentina Psoriasis market, by class, 2018-2030 (USD Million)
Table 101 Argentina Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 102 Argentina Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 103 Argentina Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 104 Middle East & Africa Psoriasis market, by country, 2018-2030 (USD Million)
Table 105 Middle East & Africa Psoriasis market, by class, 2018-2030 (USD Million)
Table 106 Middle East & Africa Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 107 Middle East & Africa Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 108 Middle East & Africa Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 109 South Africa Psoriasis market, by class, 2018-2030 (USD Million)
Table 110 South Africa Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 111 South Africa Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 112 South Africa Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 113 Saudi Arabia Psoriasis market, by class, 2018-2030 (USD Million)
Table 114 Saudi Arabia Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 115 Saudi Arabia Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 116 Saudi Arabia Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 117 UAE Psoriasis market, by class, 2018-2030 (USD Million)
Table 118 UAE Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 119 UAE Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 120 UAE Psoriasis market, by distribution channel, 2018-2030 (USD Million)
Table 121 Kuwait Psoriasis market, by class, 2018-2030 (USD Million)
Table 122 Kuwait Psoriasis market, by treatment, 2018-2030 (USD Million)
Table 123 Kuwait Psoriasis market, by route of administration, 2018-2030 (USD Million)
Table 124 Kuwait Psoriasis market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Psoriasis market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and application outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Psoriasis market dynamics
Figure 12 Psoriasis market: Porter’s five forces analysis
Figure 13 Psoriasis market: PESTLE analysis
Figure 14 Class market, 2018-2030 (USD Million)
Figure 15 Tumor Necrosis Inhibitor market, 2018-2030 (USD Million)
Figure 16 Interleukin Inhibitors market, 2018-2030 (USD Million)
Figure 17 Vitamin D Analogues market, 2018-2030 (USD Million)
Figure 18 Corticosteroids market, 2018-2030 (USD Million)
Figure 19 Others market, 2018-2030 (USD Million)
Figure 20 Treatment market, 2018-2030 (USD Million)
Figure 21 Topicals market, 2018-2030 (USD Million)
Figure 22 Systemic market, 2018-2030 (USD Million)
Figure 23 Biologics market, 2018-2030 (USD Million)
Figure 24 Route of Administration market, 2018-2030 (USD Million)
Figure 25 Oral market, 2018-2030 (USD Million)
Figure 26 Parenteral market, 2018-2030 (USD Million)
Figure 27 Topical market, 2018-2030 (USD Million)
Figure 28 Distribution Channel market, 2018-2030 (USD Million)
Figure 29 Hospital Pharmacies market, 2018-2030 (USD Million)
Figure 30 Retail Pharmacies market, 2018-2030 (USD Million)
Figure 31 Other Pharmacies market, 2018-2030 (USD Million)
Figure 32 Psoriasis market revenue, by region
Figure 33 Regional marketplace: Key takeaways
Figure 34 North America Psoriasis market, 2018-2030 (USD Million)
Figure 35 U.S. country dynamics
Figure 36 U.S. Psoriasis market, 2018-2030 (USD Million)
Figure 37 Canada country dynamics
Figure 38 Canada Psoriasis market, 2018-2030 (USD Million)
Figure 39 Mexico country dynamics
Figure 40 Mexico Psoriasis market, 2018-2030 (USD Million)
Figure 41 Europe Psoriasis market, 2018-2030 (USD Million)
Figure 42 UK country dynamics
Figure 43 UK Psoriasis market, 2018-2030 (USD Million)
Figure 44 Germany country dynamics
Figure 45 Germany Psoriasis market, 2018-2030 (USD Million)
Figure 46 France country dynamics
Figure 47 France Psoriasis market, 2018-2030 (USD Million)
Figure 48 Italy country dynamics
Figure 49 Italy Psoriasis market, 2018-2030 (USD Million)
Figure 50 Spain country dynamics
Figure 51 Spain Psoriasis market, 2018-2030 (USD Million)
Figure 52 Norway country dynamics
Figure 53 Norway Psoriasis market, 2018-2030 (USD Million)
Figure 54 Sweden country dynamics
Figure 55 Sweden Psoriasis market, 2018-2030 (USD Million)
Figure 56 Denmark country dynamics
Figure 57 Denmark Psoriasis market, 2018-2030 (USD Million)
Figure 58 Asia Pacific Psoriasis market, 2018-2030 (USD Million)
Figure 59 Japan country dynamics
Figure 60 Japan Psoriasis market, 2018-2030 (USD Million)
Figure 61 China country dynamics
Figure 62 China Psoriasis market, 2018-2030 (USD Million)
Figure 63 India country dynamics
Figure 64 India Psoriasis market, 2018-2030 (USD Million)
Figure 65 Australia country dynamics
Figure 66 Australia Psoriasis market, 2018-2030 (USD Million)
Figure 67 South Korea country dynamics
Figure 68 South Korea Psoriasis market, 2018-2030 (USD Million)
Figure 69 Thailand country dynamics
Figure 70 Thailand Psoriasis market, 2018-2030 (USD Million)
Figure 71 Latin America Psoriasis market, 2018-2030 (USD Million)
Figure 72 Brazil country dynamics
Figure 73 Brazil Psoriasis market, 2018-2030 (USD Million)
Figure 74 Argentina country dynamics
Figure 75 Argentina Psoriasis market, 2018-2030 (USD Million)
Figure 76 MEA Psoriasis market, 2018-2030 (USD Million)
Figure 77 South Africa country dynamics
Figure 78 South Africa Psoriasis market, 2018-2030 (USD Million)
Figure 79 Saudi Arabia country dynamics
Figure 80 Saudi Arabia Psoriasis market, 2018-2030 (USD Million)
Figure 81 UAE country dynamics
Figure 82 UAE Psoriasis market, 2018-2030 (USD Million)
Figure 83 Kuwait country dynamics
Figure 84 Kuwait Psoriasis market, 2018-2030 (USD Million)
Figure 85 Company categorization
Figure 86 Company market position analysis
Figure 87 Strategic framework

Companies Mentioned

The major companies featured in this Psoriasis Drugs market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • AstraZeneca
  • Celgene Corporation
  • UCB S.A.
  • Merck
  • Boehringer Ingelheim International GmbH

Table Information

Report AttributeDetails
No. of Pages150
PublishedMay 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 21.12 Billion
Forecasted Market Value ( USD ) by 2030 $ 39.11 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Psoriasis Drugs Market by Drug Class, Route of Administration, Distribution Channel, Patient Severity - Global Forecast to 2030 - Product Image

Psoriasis Drugs Market by Drug Class, Route of Administration, Distribution Channel, Patient Severity - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Biologic Medications for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030 - Product Image

Biologic Medications for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
Psoriasis Therapeutics Market by Therapeutic Class, Route of Administration, Distribution Channel, End User, Disease Severity, Patient Age Group - Global Forecast to 2030 - Product Image

Psoriasis Therapeutics Market by Therapeutic Class, Route of Administration, Distribution Channel, End User, Disease Severity, Patient Age Group - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Psoriasis Treatment Market by Drug Type, Route of Administration, Disease Type, End-User, Distribution Channel - Global Forecast to 2030 - Product Image

Psoriasis Treatment Market by Drug Type, Route of Administration, Disease Type, End-User, Distribution Channel - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Product, Administration Route, Distribution Channel, End User, Treatment Line - Global Forecast to 2030 - Product Image

TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Product, Administration Route, Distribution Channel, End User, Treatment Line - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.